Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study (2017)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1097/IGC.0000000000000836
- Subjects: NEOPLASIAS OVARIANAS; ANTINEOPLÁSICOS; RESULTADO DE TRATAMENTO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2017
- Source:
- Título do periódico: International journal of gynecological cancer
- ISSN: 1048-891X
- Volume/Número/Paginação/Ano: v. 27, n. 1, p. 50-58, 2017
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
- Licença: cc-by-nc-nd
-
ABNT
OZA, Amit M. e HEGG, Roberto. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, v. 27, n. 1, p. 50-58, 2017Tradução . . Disponível em: https://doi.org/10.1097/IGC.0000000000000836. Acesso em: 19 abr. 2024. -
APA
Oza, A. M., & Hegg, R. (2017). Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study. International journal of gynecological cancer, 27( 1), 50-58. doi:10.1097/IGC.0000000000000836 -
NLM
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1097/IGC.0000000000000836 -
Vancouver
Oza AM, Hegg R. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study [Internet]. International journal of gynecological cancer. 2017 ; 27( 1): 50-58.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1097/IGC.0000000000000836 - Cancer de ovario
- Vias e esquemas de administração dos hormônios esteróides
- Eficácia, tolerabilidade e controle de ciclo de um contraceptivo oral sem estrogênio contendo 30 mcg de levonorgestrel (minipílula)
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer
- First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor Receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial
- Galactorreia: sindrome hiperprolactinemica
- Como diagnosticar e tratar sindrome do climaterio
- Hormonioterapia de reposicao e cancer de mama
Informações sobre o DOI: 10.1097/IGC.0000000000000836 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
